Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 11Phase 3 5Phase 1/2 4Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Pathologic Complete Response 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 38Specimen Handling 37Magnetic Resonance Spectroscopy 26Biopsy 26Cyclophosphamide 25Carboplatin 25fludarabine 21Nivolumab 20Gemcitabine 18Dexamethasone 18Paclitaxel 15Rituximab 13Bevacizumab 13Pemetrexed 12Docetaxel 12atezolizumab 11Cisplatin 11Lenalidomide 10Ipilimumab 10Fulvestrant 10venetoclax 9Prednisone 9Oxaliplatin 9olaparib 8fludarabine phosphate 8belantamab mafodotin 8Temozolomide 8Injections 8Fluorouracil 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Azacitidine × 30 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04742101 2026-05-18

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Servier

Phase 1/2 Completed
57 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT04687761 2026-05-13

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

PETHEMA Foundation

Phase 1/2 Completed
113 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04493138 2026-05-04

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡